IL17A and heart failure: The title compounds’ anti-heart failure action could be mediated via binding or inhibiting tyrosine hydroxylase, BETA-1 subunit of guanylyl cyclase, BK channel, AT1 receptor antagonist, AT1 receptor antagonist combination with PPAR agonist, thermolysin, macrocyclic IL-17A antagonists, and human soluble guanylate cyclase.